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Kynurenine is a potential contributor to hypotension in animal and human sepsis. The present study was
designed to examine whether the voltage-dependent Kþ channels encoded by the KCNQ gene family
(Kv7 channels) mediate vasodilator effects of kynurenine and whether modulation of these channels
ameliorates hypotension caused by this compound. Rat aortas and mesenteric arteries or human omental
arteries without endothelium were used. Some rings were incubated with the selective Kv7 channel
inhibitor linopirdine (10 mM). L-Kynurenine (10 mMe1 mM) induced concentration-dependent relaxation
in rat aortas and mesenteric arteries as well as human omental arteries, whereas linopirdine abolished
the relaxation. L-Kynurenine (1 mM) produced hyperpolarization of vascular smooth muscle, which was
reversed by linopirdine (10 mM). Wistar rats received L-kynurenine (1 mM) iv and subsequent linopirdine
(10 mM) iv under 3% sevoﬂurane inhalation. L-Kynurenine iv caused hypotension, whereas linopirdine iv
partially reversed it. In conclusion, kynurenine dilates arteries from rats as well as humans via Kv7
channels in the vascular smooth muscle. In rats, this tryptophan metabolite causes hypotension, which is
partly counteracted by Kv7 channel inhibition. These results suggest that modulation of Kv7 channels
may be a novel strategy to treat hypotension induced by the kynurenine.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
An amino acid kynurenine is reportedly a potential novel
contributor to hypotension in animal and human sepsis (1e3).
Indoleamine 2,3-dioxygenase, which is a key enzyme in the
kynurenine pathway, biologically transforms an essential amino
acid tryptophan to kynurenine in many tissues including blood
vessels (4e6). Cytokines and endotoxin induce indoleamine 2,3-
dioxygenase protein expression in the vascular endothelial cells,
leading to increased production of kynurenine (7, 8). Indeed, the
activation of indoleamine 2,3-dioxygenase is associated with
increased plasma levels of kynurenine in patients with sepsis (2, 3).
These results suggest that inﬂammation in the endothelial cells
contributes to augmented plasma levels of kynurenine. However,: þ81 561 63 6621.
noshita).
rmacological Society.
Production and hosting by Elsevie
ons.org/licenses/by-nc-nd/4.0/).vasodilator mechanisms of kynurenine, especially toward smooth
muscle cells, have been still unclear although a previous study
indicated a partial involvement of guanylyl and adenylyl cyclase in
the relaxation (1).
Kþ channels have multiple functions in the vascular smooth
muscle cell, and among them, conventional voltage-dependent Kþ
channels are postulated to be a major determinant of vascular tone
(9, 10). The voltage-dependent Kþ channel encoded by the KCNQ
gene family (Kv7 channel) comprises ﬁve members (Kv7.1-5) (11).
Kv7.1 is mainly expressed in the heart whereas Kv7.2, Kv7.3, Kv7.4
and Kv7.5 are distributed in various organs and tissues (11, 12).
Gene and protein expression of all Kv7members has been shown in
rodent and human vascular smooth muscle cells (13e17). These
results suggest that Kv7 channels may play a major role in the
vasomotor function related to endogenous substances. However, no
experiments have been performed to study directly the actions of
kynurenine on Kv7 channels.
The present study was designed to examine whether Kv7
channels in the smooth muscle cells mediate vasodilator effects ofr B.V. on behalf of Japanese Pharmacological Society. This is an open access article
K. Sakakibara et al. / Journal of Pharmacological Sciences 129 (2015) 31e3732kynurenine and whether modulation of these channels ameliorates
hypotension caused by this amino acid.
2. Materials and methods
The Animal Care and Use Committee (#2013-3, dated June 5,
2012), and the responsible Human Ethics Board (#12-010, dated
June 22, 2012) at Aichi Medical University School of Medicine
(Aichi, Japan) approved this study. This investigation conforms to
the principles outlined in the Declaration of Helsinki. The written
informed consent was obtained from each patient in this study.
2.1. Tissue preparation for ex vivo studies
Thirty-eight male Wistar rats (12e16 weeks of age) were
anesthetized with inhalation of 5% sevoﬂurane. Thoracic aortas and
the ﬁrst order (main) mesenteric arteries were simultaneously
harvested after the rats were sacriﬁced by exsanguination. The
omental arteries (0.5e1.0mm in diameter) in the greater omentum,
which was obtained from patients scheduled for the elective gastric
surgery, were also harvested. These patients (ﬁve patients [male
four, female one], 39e70 yr) were without heart disease as well as
coronary risk factors including diabetes mellitus, hypertension,
hypercholesterolemia and smoking habit. All in vitro experiments
were performed using arteries without endothelium in modiﬁed
KrebseRinger bicarbonate solution (control solution) of the
following composition (mM): NaCl 119, KCl 4.7, CaCl2 2.5, MgSO4
1.17, KH2PO4 1.18, NaHCO3 25, and glucose 5.5. Endothelial cells of
these arterial rings were removed mechanically by gentle rubbing
of the lumen with a cotton swab or needle insertion to avoid the
modiﬁcation mediated by endothelium-derived vasodilator sub-
stances. The reason of endothelial cell removal in this study is to
avoid endogenous kynurenine production in the endothelial cells
(7, 8).
2.2. Vasomotor reactivity studies
Each ring was connected to an isometric force transducer and
suspended in an organ chamber ﬁlledwith 10ml of control solution
(37 C, pH 7.4) bubbled with 95% O2e5% CO2 gas mixture. The ring
was gradually stretched to the optimal point of its length-tension
curve as determined by the contraction to an a-adrenoceptor
agonist phenylephrine (0.3 or 1 mM for rat aortic and mesenteric
arterial rings, respectively) or a prostaglandin H2/thromboxane
receptor agonist 9,11-dideoxy-11a,9a-epoxymethanoprostaglandin
F2a (U46619, 0.03 mM for human omental arterial rings) (18,19). The
optimal resting force was achieved at approximately 1.5 g for rat
aortic rings and 1.0 g for rat mesenteric and human omental arterial
rings (18, 19). The removal of endothelial cells was veriﬁed by the
absence of relaxation in response to acetylcholine (1 mM) for rat
aortic and mesenteric arterial rings and bradykinin (1 mM) for hu-
man omental arterial rings (18, 19). Thereafter, rings were incu-
batedwith a depolarizing agent, potassium chloride (KCl, 30mM), a
conventional voltage-dependent Kþ channel inhibitor 4-
aminopyridine (1 mM) or a selective Kv7 inhibitor linopirdine
(10 mM) for 15 min. The concentration of 4-aminopyridine is rela-
tively selective to block conventional voltage-dependent Kþ chan-
nel current (9, 20) and that of linopirdine has been proved to
selectively and completely inhibit Kv7 channel activity in arterial
smooth muscle cells (21). Some rat mesenteric arteries were
simultaneously incubated with a soluble guanylyl cyclase inhibitor,
1H-[1,2,4]oxadiazolo[4,3,-a]quinoxaline-1-one (ODQ, 10 mM) (22),
an adenylyl cyclase inhibitor, 9-(Tetrahydro-2-furanyl)-9H-purin-
6-amine (SQ22536, 100 mM) (23), an activator of protein kinase C,
phorbol-12-myristate-13-acetate (PMA, 0.1 mM) or [arg8]-vasopressin acetate salt (AVP, 0.1 mM). Five min after completion of
the incubation, phenylephrine (0.1e1 mM for rat aortic and
mesenteric arterial rings) or U46619 (0.01e0.03 mM for human
omental arterial rings) was added to the chambers to obtain sub-
maximal contraction of arterial rings. These concentrations of ag-
onists were selected to achieve the same submaximal contraction
in arterial rings studied in parallel. During submaximal contraction,
which reached plateau 10e15 min after the addition of contractile
agents, concentration-response curves to L-kynurenine
(10 mMe1 mM) or a selective Kv7 channel opener ﬂupirtine ma-
leate salt (ﬂupirtine, 0.1e10 mM) were obtained in a cumulative
fashion with 4e6 min interval. The relaxation was expressed as a
percentage of the maximal relaxation in response to papaverine
(300 mM), which was added at the end of experiments to produce
the maximal relaxation (100%) of arterial rings (18, 19).
2.3. Measurement of membrane potential
Rat mesenteric arterial ringswithout endotheliumwere ﬁxed on
the bottom of an experimental chamber. The arteries were
continuously perfused with control solution (37 C) bubbled with
95% O2e5% CO2 gas mixture. A glass microelectrode (tip resistance
40e80 MU) ﬁlled with KCl (3 M) and held by a micromanipulator
(Narishige, Tokyo, Japan), was inserted into a smooth muscle cell
from the adventitial side of the vessel (18, 25). A recording ampliﬁer
(Electro 705, World Precision Instruments Inc., Sarasota, FL, U.S.A.)
ampliﬁed the electrical signal, and a data-acquisition program
(PowerLab™, ADInstruments Pty Ltd., Bella Vista, Australia) dis-
played and recorded changes in membrane potential on a com-
puter. The validity of a successful impalement was assessed by a
sudden negative shift followed by a stable negative voltage for
more than 2 min (18, 25). Resting membrane potentials and
changes in membrane potentials in response to L-kynurenine
(1 mM) and the subsequent linopirdine (10 mM) were evaluated.
2.4. Measurement of hemodynamics
Six male Wistar rats inhaled sevoﬂurane (5%) in oxygen (50%)
and catheters were indwelled in the femoral artery and vein. After
the preparation, L-kynurenine (1 mM) was intravenously injected
under sevoﬂurane (3%) inhalation. Linopirdine (10 mM) was sub-
sequently administered 5min after the injection. These intravenous
doses were determined by referring the maximum vasodilator ef-
fect of L-kynurenine in the current study as well as a previous study
(1) and the previously reported maximum inhibitory effect of
linopirdine on Kv7 channel activity in arterial smooth muscle cells,
respectively (21). The rat blood volume of 6 ml per 100 g body
weight was employed to the calculation (24). Changes in blood
pressure and heart rate were simultaneously monitored by the
BSM-2400 monitoring system (Nihon Kohden Co, Tokyo, Japan).
2.5. Drugs
The following pharmacological agents were used: 4-
aminopyrdine, AVP, dimethyl sulfoxide, ﬂupirtine, KCl, L-kynur-
enine, phenylephrine, ODQ, PMA, SQ22536 and U46619 (Sigma
Aldrich Inc., St. Louis, MO, U.S.A.), and linopirdine (Tocris Cookson
Ltd., Bristol, UK). This study used L-kynurenine, but not D-kynur-
enine since L-kynurenine is a key intermediate in the breakdown
pathway of tryptophan (1). Drugs were dissolved in distilled water
such that volumes of <60 ml are added to the perfusion system. The
stock solution of L-kynurenine or those of ﬂupirdine, ODQ, PMA,
and Tiron were prepared in hydrochloric acid and dimethyl sulf-
oxide, respectively. The highest concentration of hydrochloric acid
or dimethyl sulfoxide was 290 and 1.74 mM, respectively. Our
Fig. 1. L-kynurenine (10 mMe1 mM)-induced dilation of rat aortas (A and B) as well as rat mesenteric arteries (C) and human omental arteries (D) without endothelium, in the
absence or in the presence of KCl, 4-aminopyridine or linopirdine. The panel A shows representative tracings of changes in tension of the rat aortic ring in response to the cu-
mulative addition of L-kynurenine from 10 mM to 1 mM (shown as black dots) with or without linopirdine (10 mM). The ring was contracted with phenylephrine 1 mM (Phe) and
maximally dilated with papaverine (300 mM, PPV). The data were expressed as means ± SE; n refers to the number of rats or patients from which the artery was taken, and they
were expressed as percent of maximal relaxation induced by papaverine (300 mM). Differences between the control artery and the artery treated with KCl or linopirdine are
statistically signiﬁcant (*: P < 0.05).
Table 1







Mesenteric artery 0.75 ± 0.06 0.06 ± 0.02 8.85 ± 2.86
Aorta 1.02 ± 0.13 0.63 ± 0.10* 62.0 ± 4.35*
Mean ± SE, *: P < 0.05 vs. Mesenteric artery.
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hicles do not affect vasomotor function in our experimental con-
dition (19). The concentrations of drugs are expressed as the ﬁnal
molar concentration.
2.6. Statistical analysis
Statistical analysis was performed using PASW Statistics 18™
(IBM Japan Inc., Tokyo, Japan). The distributions of the continuous
variables were expressed as the means ± SE. Data were analyzed by
one-way ANOVA or two-way ANOVAwith Scheffe's test for statistic
signiﬁcance. Differences were considered to be statistically signif-
icant when P is < 0.05.
3. Results
3.1. Vasomotor reactivity studies
L-kynurenine induced concentration-dependent relaxation in
rat mesenteric arteries (0.3 mMe1 mM) and aortas (1 mMe1 mM),
whereas the selective Kv7 inhibitor linopirdine, as well as a depo-
larizing agent KCl, but not the conventional voltage-dependent Kþ
channel inhibitor 4-aminopyridine abolished the relaxation (Fig. 1).
Consistently with these results, L-kynurenine (0.3 mMe1 mM)
caused relaxation in the human omental arteries, which was
abolished by linopirdine (Fig. 1). Linopirdine (10 mM) induced sig-
niﬁcant contraction in the rat aortas (62.0 ± 4.4% compared with
phenylephrine [0.3 mM]-induced contraction), whereas it did not
produce the contractile response in rat mesenteric arteries
(Table 1). By adjustment of the doses of phenylephrine (0.1e1 mM
for rat aortic and mesenteric arterial rings) or U46619
(0.01e0.03 mM for human omental arterial rings), submaximal
contraction to contractile agents did not differ among studiedgroups in parallel (0.75e0.85 g for rat mesenteric arterial rings,
1.20e1.32 g for rat aortic rings, and 1.70e1.98 g for human omental
arterial rings, respectively, NS, Fig. 1).
In rat mesenteric arteries, the selective Kv7 channel opener
ﬂupirtine (0.1e10 mM) induced concentration-dependent relaxa-
tion, which was completely inhibited by linopirdine (10 mM), but
not by 4-aminopyridine (1 mM) (Fig. 2). In Fig. 2, submaximal
contraction to phenylephrine did not differ among the studied
group in parallel (1.06e1.15 g, NS). The soluble guanylyl cyclase
inhibitor ODQ (10 mM), the adenylyl cyclase inhibitor SQ22536
(100 mM), the protein kinase C activator PMA (0.1 mM) or AVP
(0.1 mM) did not alter L-kynurenine-induced relaxation of rat
mesenteric arteries (Figs. 3 and 4). In Figs. 3 and 4, submaximal
contraction to phenylephrine did not differ among studied
groups in parallel (0.74e0.85 g for Fig. 3 and 0.77e0.99 g for
Fig. 4, NS).3.2. Measurement of membrane potential
Consistently with results in the hemodynamic measurements, L-
kynurenine (1 mM) hyperpolarized rat mesenteric arteries and
subsequent linopirdine (10 mM) reversed the hyperpolarization
(Fig. 5).
Fig. 2. The selective Kv7 opener ﬂupirtine (0.1e10 mM)-induced dilation of rat
mesenteric arteries without endothelium, in the absence or the presence of 4-
aminopyridine or linopirdine. The data were expressed as means ± SE; n refers to
the number of rats from which the mesenteric artery was taken, and they were
expressed as percent of maximal relaxation induced by papaverine (300 mM). The
difference between the control artery and the artery treated with linopirdine is sta-
tistically signiﬁcant (*: P < 0.05).
Fig. 4. L-kynurenine-induced dilation of rat mesenteric arteries without endothelium,
in the absence or the presence of the protein kinase C activator PMA (0.1 mM) or AVP
(0.1 mM). The data were expressed as means ± SE; n refers to the number of rats from
which the mesenteric artery was taken, and they were expressed as percent of
maximal relaxation induced by papaverine (300 mM).
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L-kynurenine (1mM) iv caused hypotension, which was reached
a plateau at ﬁve min after the injection (Fig. 6). Administration of
linopirdine (10 mM) partially reversed the hypotension (Fig. 6).
Neither L-kynurenine nor linopirdine iv affected heart rate
throughout the experiment (Fig. 6).
4. Discussion
L-kynurenine induced relaxation or hyperpolarization of human
omental arteries as well as rat mesenteric arteries and aortas,Fig. 3. L-kynurenine-induced dilation of rat mesenteric arteries without endothelium, in t
adenylyl cyclase inhibitor SQ22536 (100 mM). The data were expressed as means ± SE; n re
expressed as percent of maximal relaxation induced by papaverine (300 mM).which was abolished by a selective Kv7 inhibitor linopirdine, but
not by a conventional voltage-dependent Kþ channel inhibitor 4-
aminopyridine, indicating that this L-tryptophan metabolite cau-
ses vasodilation largely via Kv7 activation (14, 17). This conclusion
is supported by the results that linopirdine completely inhibited a
selective Kv7 channel opener ﬂupirtine-induced vasorelaxation,
verifying the selectivity of linopirdine on Kv7 channels (26). Indeed,
linopirdine-sensitive currents are activated at more negative volt-
ages than conventional voltage-dependent Kþ channels, and,
therefore, they are insensitive to 4-aminopyridune in the rat
mesenteric arterial smooth muscle cells (21). It is also crucial to
note that KCl (30 mM) did not completely remove a component of
the kynurenine-induced relaxation. Factors other than Kþ channelshe absence or the presence of the soluble guanylyl cyclase inhibitor ODQ (10 mM, the
fers to the number of rats from which the mesenteric artery was taken, and they were
Fig. 5. Changes in the membrane potential of rat mesenteric arteries without endothelium in response to L-kynurenine (1 mM) and the effect of subsequent linopirdine (10 mM). The
left panel shows a representative tracing of changes in membrane potential (mV) of the rat mesenteric artery in response to L-kynurenine (1 mM shown as A) and the subsequent
addition of linopirdine (10 mM shown as B). The right panel demonstrates the cumulative data. The data were expressed as means ± SE; n refers to the number of rats fromwhich the
mesenteric artery was taken. The difference between the resting membrane potential and the membrane potential after the L-kynurenine application is statistically signiﬁcant (*:
P < 0.05).
K. Sakakibara et al. / Journal of Pharmacological Sciences 129 (2015) 31e37 35should mediate it since the part was seen in the condition with the
relatively higher concentrations of a depolarizing agent (9).
The Kv7 channel family comprises ﬁve members (Kv7.1-5) (11).
Kv7.1 is mainly expressed in the heart whereas Kv7.2, Kv7.3, Kv7.4
and Kv7.5 are widely distributed in various organs and tissues (11,
12). In the blood vessels, Kv7.4 is the most abundant mRNA in theFig. 6. Percent changes in mean blood pressure and heart rate induced by L-kynur-
enine (1 mM) iv under sevoﬂurane (3%) inhalation, and the effect of subsequent
linopirdine (10 mM) iv. The data were expressed as means ± SE; n refers to the number
of rats, and they were expressed as the percent of baseline mean blood pressure
(72.0 ± 2.9 mmHg) and heart rate (282.8 ± 17.0 mmHg). Differences in mean blood
pressure between the baseline and each time point after the commencement of the
experiment are statistically signiﬁcant (*: P < 0.05).mouse aorta, carotid artery femoral artery and mesenteric artery
(14), whereas Kv7.1 is the most dominant in the mouse portal vein
(13). In rats, expression of Kv7.1 or Kv7.4 was proved in the third-
order mesenteric arteries, thoracic aorta, intrapulmonary arteries
and the Gracilis muscle artery (15, 16). In human mesenteric ar-
teries, Kv7.4mRNA is consistently expressed, whereas expression of
Kv7.1, Kv7.3, and Kv7.5 mRNAs is more variable, and Kv7.2 mRNA is
undetectable (17). Therefore, Kv7.4 is probably the most likely
candidate to mediate kynurenine-induced arterial dilation
including that in humans. It should also be emphasized a crucial
role of Kv7 expressed on vascular smooth muscle cells in the
kynurenine's vasodilator effect since Kv7 subunits are located in
the arterial smooth muscle layer (17). In the current study, lino-
pirdine induced contraction of the rat aortas but not of the rat main
mesenteric arteries. These results indicate the roles of Kv7 in basal
vascular tone are variable dependently on regions where the artery
exists.
Accumulating evidence suggests that protein kinases A, G, and C
regulate conventional voltage-dependent Kþ channels in vascular
smooth muscle cells (10). Vasodilators stimulate adenylyl cyclase,
which leads to increased cyclic AMP production and protein kinase
A activity, resulting in activation of these channels (10). Activation
of guanylyl cyclase by vasodilators is also capable of causing an
increase in cyclic GMP production and protein kinase G activity,
which enhances conventional voltage-dependent Kþ channel ac-
tivity (10). In the current study, neither a soluble guanylyl cyclase
inhibitor ODQ nor an adenylyl cyclase inhibitor SQ22536 altered L-
kynurenine-induced vasorelaxation, indicating that the kynurenine
causes Kv7 activation independently of these kinases. These results
are in contrast with a previous study that the kynurenine at least
partly induces vasodilation via activation of guanylyl and adenylyl
K. Sakakibara et al. / Journal of Pharmacological Sciences 129 (2015) 31e3736cyclase pathways (1). Experimental conditions and species differ-
ences (cultured rat aortic smoothmuscle cells and porcine coronary
arteries vs. isolated rat aortas and mesenteric arteries, and human
omental arteries in the current study) may play roles in such a
discrepancy between previous and current studies. Vasoconstric-
tors induce diacylglycerol and consequent protein kinase C acti-
vation, resulting in inhibition of conventional voltage-dependent
Kþ channels in vascular smooth muscle cells (10). Indeed, the
physiological concentrations of AVP (0.01e0.1 nM) via activation of
protein kinase C reportedly inhibit the Kv7 current caused by
synthetic Kv7 openers including ﬂupirtine (21, 27, 28). Kynurenine
probably acts on Kv7 channels via different mechanisms from
synthetic Kv7 openers since the higher concentration of a protein
kinase C activator PMA (0.1 mM) or AVP (0.1 mM) failed to alter
vasorelaxation in response to L-kynurenine in the current study.
More importantly, a Kv7 inhibitor linopirdine completely inhibited
L-kynurenine-induced vasorelaxation, and it partially reversed hy-
potension and hyperpolarization induced by L-kynurenine. These
results suggest that a potentially therapeutic role of selective Kv7
inhibitors, but not AVP, in the hypotension mediated by increased
production of kynurenine in variable pathological conditions as
follows.
Indoleamine 2,3-dioxygenase, which is a key enzyme in the
kynurenine pathway, biologically transforms an essential amino
acid tryptophan to kynurenine in many tissues including blood
vessels, resulting in normal plasma kynurenine concentration of
about 1 mM (4e6). Plasma levels of kynurenine are expected to
reach the pathological range since many pathological changes are
known to cause substantial effects on the kynurenine generation
and excretion (4, 5). The activation of indoleamine 2,3-dioxygenase
is associated with increased plasma levels of kynurenine up to
20 mM in patients with sepsis (2, 3). Interferon-g augments the
indoleamine 2,3-dioxygenase protein expression in the human
aortic endothelial cells, leading to increased levels of kynurenine to
10 mM in a culture medium (8). These results suggest that inﬂam-
mation plays a major role in augmented plasma levels of kynur-
enine. Renal dysfunction including uremia in humans is capable of
enhancing plasma kynurenine levels up to 5 mM, being supported
by the physiological evidence that the glomeruli ﬁlter kynurenine
(29, 30). Augmented metabolism of tryptophan by indoleamine
2,3-dioxygenase contributes to a three-times increase in plasma
kynurenine levels in patients after major trauma (31). Obesity is
accompanied by the activation of indoleamine 2,3-dioxygenase in
the adipose tissues, resulting in doubled plasma levels of kynur-
enine (6). These studies draw a conclusion that co-existence and
the combination of any above disease state may further increase
plasma levels of kynurenine in humans to the concentration range
that was evaluated in the current study. It is unclear, however,
whether co-existence of different disorders can further increase
plasma levels of kynurenine in humans up to the concentration
range used in this study.
This is the ﬁrst study to demonstrate that pathological con-
centrations of an amino acid kynurenine dilate arteries from rats as
well as humans via activation of Kv7 channels in the vascular
smooth muscle cells. Consistently with these results, this trypto-
phan metabolite caused hypotension, which was partially reversed
by the Kv7 channel inhibition. These results suggest that Kv7
channels play a crucial role in the regulation of vasomotor function
in the pathological conditions. Modulation of these channels and
the blockade of kynurenine formation may be novel strategies to
treat hypotension induced by kynurenine.
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